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Abstract 
TG119 is a report published by The American Association of Physicists in 
Medicine (AAPM) to be used for Intensity Modulated Radiation Therapy (IMRT) 
commissioning. Nine institutions contributed to TG119 by creating and delivering five 
IMRT cases of varying complexity. Each institution measured the dose of each plan and 
formed a confidence limit (CL) such that CL = |mean| + 1.96 SD. The given confidence 
limits form a baseline for other institutions to be used in IMRT commissioning. 
However, since the publication of TG119 in 2009, new techniques have emerged in the 
field of radiation therapy including Volumetric Arc Therapy (VMAT) and the Flattening 
Filter Free (FFF) mode in advanced linear accelerators. Our goal in this work is to verify 
the feasibility of using TG119 to commission VMAT and FFF systems and to set a 
benchmark for other institutions to use. 
We created 48 plans of the five sites given in TG119 in addition to a “real” head 
and neck (HN) case. For each site, we planned IMRT and VMAT using 6 MV and 10 MV, 
Flattening Filter (FF) and FFF modes (6x2x2x2 = 48 plans). All our plans were created on 
the Eclipse treatment planning system (Varian Medical Systems, Palo Alto, CA) and 
delivered on three beam-matched TrueBeam linear accelerators (Varian Medical System) 
at Duke University Medical Center. 
  
v
Measurements were taken using an ion chamber, films, and a pseudo-3D diode 
array (Delta4), and compared to the planned doses.  Confidence limits were determined 
using the approach of TG119 (CL = |average mean deviation| + 1.96 SD). We used the 
student’s paired t-test to determine any statistically significant differences between 
IMRT and VMAT, FF and FFF for 6 MV and 10 MV.   
 The majority of the ion chamber measurements (94%) agreed with the planned 
doses to within 3%. The majority of errors > 3% involved the HN IMRT plans, either 
TG119 or “real”. For film measurements, we used gamma parameters of 3%, 3mm with a 
20% threshold. All films met an acceptability criterion of <= 10% of pixels failing gamma. 
As for Delta4, gamma parameters of 3%, 3mm with a 5% threshold were used. All plans 
met the acceptability criterion of 90% of pixels passing (average 99.7% +/- 0.8%). A 
second analysis was performed using 2%, 2mm gamma parameters, wherein almost all 
plans met the 90% passing rate criterion (average 98.9% +/- 2.5%).  
                 Confidence limits were established for ion chamber (3.1%), film (6%), and 
Delta4 (3.1%) measurements. All the confidence limits were comparable to TG119 
institutions. We recommend that non-clinical plans (e.g. 10 MV HN plans) not be 
included in TG119 evaluations. We also recommend that film continue to be used as the 
gold standard of multi-dimensional measurements, rather than be replaced by diode-
based technology. 
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1. Introduction  
1.1 Linear Accelerators 
1.1.1 The Traditional Design 
Linear accelerators accelerate charged particles using electric fields in the 
direction of the particles’ propagation [1]. The charged particles are electrons produced 
by heating a filament. By applying a voltage, these electrons are guided to enter a 
waveguide. Simultaneously, an electric field enters the waveguide from an RF wave 
source, and the waves accelerate the electrons until a desired kinetic energy is achieved. 
In radiotherapy clinics, the electrons’ energies are in the MeV range. These high-energy 
electrons can be used directly for treatment or to produce x-ray beams. Photons are 
produced when the electrons strike a tungsten target. In MeV energy range, the 
produced photons are mainly in the forward direction as opposed to keV beams where 
the probability of x-ray direction is similar in all angles. 
Conventionally, in order to produce an adequate coverage throughout the tumor 
volume, a flattening filter is inserted in the photon beam’s path. The flattening filter is a 
conic shape high Z material. The photons exit this filter with a homogeneous fluence (as 
measured at a depth of 10 cm in a water phantom) but varying mean energy across the 
plane. The beam has a higher mean energy (i.e. "harder" spectrum) in the center and 
lower mean energy (i.e. "softer" spectrum) towards the beam edges. In shallow depths, 
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however, this property is seen as horns at the sides of a beam profile and a dip in the 
center, but at a certain depth the profile becomes flat.  
Below the target and the flattening filter, there are two sets of jaws to collimate 
the beams. In Varian (Varian Medical Systems, Palo Alto, CA) linear accelerators, the 
upper jaws are Y1 and Y2, which move towards the gantry or away from it when the 
collimator’s angle is at zero. Below them are the X1 and X2 jaws which move in the 
perpendicular direction (left – right when the collimator is at zero angle). In modern 
VARIAN linear accelerators, a set of multi-leaf collimators (MLCs) is inserted under the 
X jaws. These MLCs move in the same direction as the lower jaws. The MLCs used in 
this study are Varian’s Millennium-120, which are formed of 120 leaves equally divided 
between two banks (Bank A and Bank B). They are sized such that the projection at 100 
cm from the source would be 5 mm thick for the central 40 leaves and 1 cm for the 
remaining 10 on each side within a bank. The MLCs are used to shape the beam to 
achieve high conformity around the tumor volume while shielding the surrounding 
tissue and organs at risk from photons. More recently, these MLCs have been developed 
to modulate the intensity within an open beam. This beam modulation is achieved by 
varying the location and speed of the MLCs within the treatment fields. Dose rate has 
units of MU/min where MU stands for Monitor Units. In radiotherapy, the monitor unit 
is a representation of the machine’s output. This output is defined when the machine is 
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commissioned and is calibrated periodically. The output is monitored by a set of ion 
chambers above the jaws. 
 
 
 
 
 
 
 
1.1.2 Flattening-Filter Free Mode 
In the megavoltage energy range, X-rays are produced from the target in a 
forward direction relative to the direction of electrons incident upon the target [1]. 
Flattening filters have typically been inserted in the beam path in order to produce a 
uniform intensity across the field at a given depth, thereby providing a uniform dose. 
The removal of the flattening filter produces a beam with significant photon fluence (i.e. 
number of photons per cm2) variation across the field and lower average photon energy.  
A comparison of the beam profile of flattened and un-flattened fields is shown in Figure 
2. The higher photon fluence along the central axis allows for a high dose delivery rate, 
shortening patient treatment time. The lower photon fluence off-axis reduces out-of-field 
dose to normal tissue.  The out-of-field dose is further lowered by the reduction of head 
Figure 1: A simplified diagram of a LINAC 
RF  
\
Table top 
Gantry 
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scatter from the linear accelerator due to both the removal of the flattening filter from 
the beam path (no scatter will occur within the flattening filter) and by the lower average 
photon energy. By reducing the out-of-field dose, the patient's risk of a secondary cancer 
induction is also lowered. 
 
In our experience, the ideal treatment site for FFF beams is a small tumor (4cm 
diameter or less) prescribed to receive a high dose per fraction.  As the tumor is small, 
the photon fluence does not vary significantly across the field. Therefore only minor 
field modulations with MLCs are required to produce good dosimetry.  With minor 
modulations the MU increase is minimal. Therefore a large reduction in treatment time 
can be achieved.  As the size of the tumor increases, the required MLC modulation to 
produce a flat field of adequate size increases along with the MU per field. The 
treatment of large tumors would not be appropriate for a FFF beam. 
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Figure 2: 10 MV beam profile (left) vs. 10 MV FFF beam profile (right) 
 
Due to the reduced average energy and photo-neutron fluence in comparison to 
flattened beams, the same vaults can be used for FFF beams. The clinical physicist 
should remember that for FFF beams the conventional definition of flatness and 
symmetry might not be applicable [9]. The flatness for a flattened beam is typically 
measured at depths of dmax and 10 cm in water.  
As a new technology in radiotherapy treatment delivery, it is important to fully verify 
the FFF commissioning. We have tested the quality assurance procedures used for FF 
radiation by TG119 to see if they may also be implemented for FFF radiation. 
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1.2 Radiation Delivery Modalities 
1.2.1 3D Conformal 
Computerized tomography (CT) and MLCs made the ability to conform the 
beam to the tumor volume while shielding the organs at risk from the main radiation 
beam achievable. Varian introduced their commercial MLCs in 1990 to the European 
and American markets [26]. By setting each leaf at a certain location the beam can be 
shaped around the tumor for each treatment angle. This is known in radiation oncology 
clinics as 3D conformal radiation therapy (3D CRT). The 3D CRT steps are as following: 
a. Image the patient with a high quality 3D imaging device (typically CT). In this 
step the patient’s setup and the choice of immobilization devices take place. 
b. Contour the tumor volume and critical organs. 
c. On a computer-based treatment planning system (TPS), create a treatment 
plan. 
d. Calculate the dose to the tumor and organs at risk using an accurate dose 
calculation algorithm. We used the Analytical Anisotropic Algorithm (AAA) 
in our study. 
e. Evaluate the plan using dose volume histograms (DVHs) which describe how 
much of a structure receives a given dose. In addition to DVH, isodose lines 
are used for plan evaluation. Isodose lines are lines that connect between 
points receiving an equal dose, as shown in Figure 3. 
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f. For treatment, the patient is placed in position then imaged using either kV 
or MV imaging. The patient’s position is adjusted as needed prior to 
treatment. 
 
 
    
1.2.2 IMRT 
Intensity-modulated radiation therapy (IMRT) increases the radiotherapy 
complexity beyond 3D-CRT by adding intensity modulation within each field. In 
3DCRT planning, the beams are set at chosen angles with the use of compensators and 
MLCs to conform the beam around the tumor. The needed MUs to deliver the desired 
dose are calculated by the TPS. This is known as forward planning as opposed to inverse 
planning. In inverse planning, we set the dose goals for each structure (tumor volumes 
and organs at risk). Through an optimization process, the computer finds the plan that 
Figure 3: Isodose lines in the Multitarget plan 
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best matches the given criteria. In each calculated field, the beam is modulated giving a 
variable intensity profile. 
 One way to modulate the beam’s intensity is by varying the MLCs position 
within a field. There are two classes of MLC-based IMRT, step-and-shoot and sliding-
window. For step-and-shoot delivery of a treatment field, the MLCs shift into different 
patterns in-between the beam turning on. In other words, the MLCs do not move while 
radiation is being delivered. For sliding-window delivery, the MLCs move while the 
beam is on. In both methods, the beam is off while the gantry moves to the next angle to 
deliver the following field. The sliding-window technique is also known as dynamic 
MLC delivery. Each pair of leaves would start at the same end and move in the same 
direction [1].  
In the Varian linear accelerators we have used, the MLCs used are Millinnium 
120. This MLC system by Varian is formed of 120 leaves (60 pairs). The central 40 pairs 
are 5 mm wide and the width of the remaining 20 pairs are 10 cm. These widths are of 
the projection at 100 cm from the target. 
 
 
 
 
 
Figure 4: A diagram presenting MLCs: (a) Parked. (b) Shaped to 
deliver a small dose through a window in IMRT 
(a) (b) 
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The steps for IMRT planning are similar to 3D CRT in addition to the following: 
a) Treatment beams are typically 5 to 9 equally-spaced beams. 
b) Set dose constraints to target volumes and organs at risk. 
c) The planning system creates a fluence map using an optimization method. 
d) TPS performs a leaf motion calculation (to find the machine’s ability to achieve 
the optimized fluence). 
e) The treatment planner evaluates the 3D dose distribution and re-optimizes the 
plan as necessary. 
 
In IMRT delivery, most of the beam is blocked by the multi-leaf collimator. Due 
to this fact, an error in MLC positioning can impact the dose distribution. Therefore, the 
accuracy of the MLC positioning and the stability of the leaf speed has to be tested 
periodically. In addition to that, a patient-specific QA has to be performed. In patient-
specific QA, we create a verification plan by copying the patient’s plan into a phantom 
and calculate the corresponding dose. This plan is then delivered to the phantom and a 
comparison between the TPS estimated dose and the measurement is used for analysis.  
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1.2.3 VMAT 
      The concept of Volumetric Modulated Arc Therapy (VMAT) was first 
introduced in 1995, but wasn’t commercially available until after 2008 [5]. In VMAT, the 
gantry is no longer static but rotates while the radiation is delivered.  Additionally, in 
VMAT the dose rate and gantry speed may be varied along with MLC leaf position.  
These additional variables increase the complexity of radiation treatment delivery above 
that of IMRT, highlighting the importance of adequate quality assurance techniques [6], [7].  
In VMAT the beam delivery is fast and with lower MUs in comparison to 
conventional IMRT. The gantry can perform a full rotation in 60-65 seconds, varying 
based on the manufacturer. During an arc, the MLCs keep moving back and forth to 
deliver the desired photon fluence at all angles (as opposed to one direction motion in 
conventional DMLC). Also, during the beam’s delivery, the dose rate varies.  
 
1.3 Radiation Measurement Devices 
1.3.1 Ionization Chambers 
Ionization chambers (or ion chambers) are the most commonly used dosimetric 
devices in the radiation therapy clinics. Ion chambers are formed of enclosed gas 
(typically air) within a thin wall. When the radiation hits the chamber, the air gets 
ionized and a potential difference is applied between the anode and cathode. As a result, 
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the produced ions migrate to the electrode of opposite charge. The collected charges 
form an electric current proportional to the radiation dose.  
The chamber of our choice is a thimble chamber, the most commonly used 
chamber in radiotherapy. Thimble chambers are cylindrically shaped with the wall 
being grounded and the applied potential on the central electrode. One of the most 
popular thimble chambers is the Farmer chamber. The Farmer chamber has a sensitive 
volume of 0.6 cc filled with air enclosed in graphite wall. However, smaller thimble 
chambers have been developed for small fields measurements. The miniature chambers 
are suitable for measurements in high gradient regions as well. Figure 5 shows a picture 
of a Farmer chamber and a 0.01 cc ion chamber. 
The electron current collected by the chamber is displayed using an electrometer. 
Typically, the electrometer supplies the chamber with voltage and displays the 
measured charge or current. The chambers are connected to the electrometer using low-
noise triaxial cables. 
 
Figure 5: 0.01 cc ion chamber (left) and a 0.6 cc Farmer chamber (right) 
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                                           Figure 6: Electrometer 
 
1.3.2 Films 
Films are usually used for qualitative analysis or for relative dosimetry [1], [26]. The 
main advantage of films is their high two-dimensional resolution information. 
Radiographic films consist of radiation-sensitive silver-halide crystals, which are 
sandwiched between gelatin emulsion coatings on both sides of the film. The emulsion 
provides the film with stiffness for film handling and stability against heat and chemical 
effects.  
When the incident photons hit the crystal lattice, they generate electrons via 
photoelectric, Compton scatter or pair-production interaction. The electrons get trapped 
in impurities where they attract silver ions to form silver atoms after they combine. For 
the grain to be developable, it has to contain at least three silver atoms. The radiation 
forms a latent image on the film, which is later rendered by developing the film using 
chemicals. 
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The amount of the black silver molecules is proportional to the radiation dose. 
After irradiation and processing, the opacity of a region in the film is used as indication 
of the radiation’s dose. Higher doses result in regions of higher opacity. The light 
opacity is defined as I0 / I, where I0 is the intensity of light without the film and I is the 
intensity of the light after passing through the film. In the clinic we use the optical 
density (OD), which is log10 of the opacity.  
When films are used for dosimetry, a calibration curve has to be created for each 
used batch. The curve relates the OD to the radiation doses. Film dosimetry is becoming 
less popular in clinics due to the difficulty of maintaining film processors. With the 
movement towards digital imaging in both radiation and diagnostic clinics, many film 
processors have been removed or neglected. 
Radiochromic films are a relatively recent development of film technology. 
Radiochromic films are insensitive to room light and do not need a film processor. These 
characteristics make them easy to use and convenient for relative dosimetry. 
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Figure 7: A radiographic film with an IMRT dose delivered 
 
1.3.3 3D Dosimetry 
Ionization chambers provide point dosimetry and films display planar dose. 
Delta4 is a pseudo 3D QA device composed of two planes of diode arrays crossing each 
other with a cylindrical phantom of PMMA (poly-methyl methacrylate) filling the space 
in between them. This phantom is 40 cm long and 22 cm in diameter. The planes consist 
of 1069 p-type silicon diodes with 0.039 mm3 cylindrical  sensitive volume and are 
arranged such that they are 5 mm away from each other in the center (6 cm x 6 cm area) 
and 1 cm apart in the remainder of the 20 cm x 20 cm panel. The data is measured by the 
detector arrays while the regions between them are estimated by interpolation. Hence it 
is a pseudo 3D device.  
The Delta4 calibration is done by removing the panels from the PMMA phantom 
and then placing them in a rectangular acrylic phantom. The central diode is then 
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calibrated against an ion chamber. During calibration, the ion chamber has its own 
PMMA phantom. First the ion chamber measurement is taken with a field size of 10 x 10 
cm2. Then it (and its phantom) is removed from the beam, and one of the diode planes is 
placed into the beam for calibration. The other diodes are calibrated relatively to the 
central one, with the field size increased to encompass them. In order to calibrate the 
diodes in a stable beam, the arrays are irradiated and then moved in directions 
perpendicular to the beam several times [4]. 
 
 
                            Figure 8: Delta4, a pseudo 3D QA device 
The detector arrays are shown in Figure 9 with the blue dots being the points 
passing the gamma criteria while the reds dots are failing points. 
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 Delta4 provides more points of measurement in comparison to ion chamber 
(point dose) or film (planar dose) methods, therefore its results might be more 
representative of the entire dose distribution’s accuracy. 
 
1.4 TG119 
The AAPM Task Group 119 [2] published their report in 2009 to set a benchmark 
for IMRT commissioning. This task group was formed after the Radiologic Physics 
Center (RPC) reported that 28% of the institutions involved failed the head and neck 
(HN) IMRT process. They produced a set of test cases in order to evaluate the IMRT 
treatment chain from simulation to delivery; these tests were for five different sites in 
addition to two preliminary tests.  
Figure 9: A screen capture from the Delta4 software showing the two 
panels and the analysis. 
 17 
The non-IMRT preliminary tests were a simple AP-PA open field and a series of 
AP-PA open fields of different sizes, used to create a stair-step dose pattern, which were 
given for calibration and to show the reliability of the assessment system for non-IMRT 
cases. These are followed by 5 IMRT plans of various complexity: multitarget, prostate, 
head-and-neck, and two Cshape targets with an internal avoidance structure.  
The multitarget structures are formed of three cylinders, 4 cm in length and 4 cm 
in diameter. The superior, central, and inferior structures are supposed to receive 50%, 
100%, and 25% of the target dose respectively. Planning goals are specified using D99 
and D10 (dose to 99% and 10% of the volume respectively) to the three cylinders. The 
plan is composed of seven IMRT fields that are at 50° intervals from the AP. The ion 
chamber measurements take place in the center of each target (with applying 4.0 cm 
superior and inferior shifts), while the film data is collected mid-phantom.  
 
 
Figure 10: MultiTarget from Eclipse 
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The prostate CTV is an ellipsoid of the following dimensions: 4.0 cm right-left, 
2.6 cm anterior-posterior and 6.5 cm superior-inferior. The PTV consists of the CTV plus 
a 0.6 cm isotropic margin. The bladder and rectum are the organs-at-risk. The planning 
goals are achieved using D95 and D5 for the prostate PTV, and using D30 and D10 for 
the organs at risk. The plan is composed of 7 fields, as in the multitarget case, which are 
at 50° intervals from the vertical. Measurements take place at the center of the PTV (the 
isocenter) and 2.5 cm posterior in the rectum. 
 
 
 
 
 
 
 
 
 
The TG119 HN consists of a large PTV that extends from the base of the skull to 
upper neck. It is 0.6 cm away from the skin and 1.5 cm away from the spinal cord, 
which, along with the parotid glands, is an avoidance structure. The dose goals are 
Figure 11: Prostate from Eclipse 
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specified by D95, D90 and D20 for the PTV, D50 for the parotids and maximum dose for 
the cord. This plan was made with nine fields in 40° intervals from the AP, with the 
measurements taken in the PTV (the isocenter) and 4.0 cm posteriorly in the center of the 
cord. The film measurements show the dose to the parotid glands in mid-phantom 
measurements. 
 
Figure 12: TG119 Head and Neck from Eclipse 
 
Cshape is an 8 cm long C-shaped target with an inner radius of 1.5 cm and an 
outer radius of 3.7 cm. This PTV surrounds a central 10 cm long - 1 cm radius cylindrical 
core with a 0.5 cm gap between the core and the PTV. This time, however, the isocenter 
is placed in the avoidance structure instead of the PTV such that the low dose / high 
gradient region is in the isocenter. One of the cases is easy with achievable goals in 
which the core gets 50% of the target dose. In the second one (hard), the core is 
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supposed to be kept to only 20% of the target dose. The goal of the hard plan is to test 
the limits of the planning and delivery system, as it is practically impossible to achieve. 
The dose goals are specified by D95 and D10 for the PTV and by D10 for the OAR. The 
beam arrangements are the same for both plans. They are composed of 9 fields that are 
in 40° intervals from the AP. Measurements take place in the isocenter (central core) and 
2.5 cm anteriorly in the PTV for both ion chamber and films. 
 
Figure 13: Cshape from Eclipse 
 
These structures are available on the AAPM website and can either be 
downloaded or drawn by the individual into the TPS. Following the planning and 
measurements steps given in the TG119, other institutions can verify their IMRT 
commissioning by comparing their confidence limit (CL) values to the TG119 values, 
where CL = |mean| + 1.96 SD.  
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The TG119 institutions used different treatment planning systems and machines 
depending on the availability to the institution. They all planned and delivered IMRT 
plans using 6 MV beams because it was the only energy available to all institutions. 
However, since the publication of TG119, new techniques have emerged in the field of 
radiation oncology. Some have become widely used, such as VMAT and FFF. In this 
work we study the feasibility of using TG119 to commission VMAT and FFF using two 
different energies (6 MV and 10 MV).  
 
1.5 Hypothesis 
In this study, we introduce two hypotheses. The first is that TG119 IMRT cases 
can be re-purposed for (1) VMAT commissioning and for (2) flattening-filter free (FFF) 
beam commissioning. The second hypothesis states that the pseudo-3D diode QA device 
(Delta4) will provide similar results to film. To test the first hypothesis, the results of the 
TG119 methodology will be compared between IMRT/VMAT, FF/FFF, and this 
study/TG119 institutions. To test the second hypothesis, the Delta4 measurements will 
be compared to film measurements. 
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2. Materials and Methods 
We followed the TG119 recommendations for planning and choice of phantoms. 
All structures are available in a DICOM format and can be downloaded from the AAPM 
website, http://www.aapm.org/pubs/tg119/default.asp. Alternatively, the structures can 
be contoured manually if preferred by the planner. 
We used a 0.01 cc chamber with a depth of 7.5cm in a solid water phantom to 
acquire point measurements of different plans. We also compared some of the 0.01 cc 
chamber measurements to 0.1 cc chamber measurements for investigation and obtained 
similar results. We used the 0.01cc chamber, however, for its better resolution in the low 
dose region. 
We CT scanned a 30x30x15 cm3 phantom with an insert for a CC01 ion chamber, 
and another one with no insert but of same dimensions for film measurements. The 
phantom consisted of solid water slabs of different thicknesses such that the ion 
chamber (or the film) was at a depth of 7.5 cm. In addition to the 0.01 cc ion chamber 
(point measurement) and EDR2 (Extended Dose Range) film measurements (2D), we 
used a pseudo3D diode device (Delta4, ScandiDos, Uppsala, Sweden). The 
homogeneous cylindrical phantom CT image provided by the vendor was used for dose 
calculations, as is done clinically. 
All treatment plans and dose calculations were done in Eclipse v 10.0.39 and 
were delivered at the TrueBeam machines at Duke University Medical Center using an 
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Aria record-and-verify system (Varian Medical Systems, Palo Alto, CA). The calculation 
grid in these plans was 2.5mm in all cases. Eight plans for each energy and each 
technique were created, yielding a total of eight preliminary plans (AP-PA and bands for 
6 MV, 6 MV FFF, 10 MV and 10 MV FFF) and forty eight site-specific plans (6 sites, IMRT 
and VMAT, 6 MV, 6 MV FFF, 10 MV and 10 MV FFF). 
 
2.1 Plans 
 
2.1.1 AP-PA 
This test is done in order to convert the MUs to dose per field while also 
eliminating the daily output fluctuations. It consists of two fields Anterior-Posterior 
(AP) and Posterior-Anterior (PA) of 10x10 cm2 field size. 200 cGy/ fraction (100 cGy / 
field) was delivered to the isocenter and was measured with the ion chamber. The open 
field AP-PA measurement in the isocenter was done to establish the cGy/nC for the ion 
chamber during the measurement session (i.e. to obtain a conversion factor that relates 
the charges measured by the ion chamber into dose in cGy).  
2.1.2 Bands 
Five open fields of various sizes were used to deliver a stair-step dose pattern 
across a 15cm field. The X jaws were fixed to a 15 cm opening, with Y1 set at +7.5 cm and 
with Y2 varying from -4.5 cm to +7.5 cm. The bands are made to test the film QA ability 
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which makes this test useful for film calibration. We used our own film calibration plan 
developed at Duke. 
 
Figure 14: Dose profile for the bands plan from Eclipse 
 
In Figure 14, the upper curve (the one that looks like stairs from side) is the 
accumulated dose from all 10 fields, while the lower curve is the contribution from each 
band. Each one of the five bands is composed of two fields an AP and a PA, thus we 
have a total of 10 fields. 
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2.1.3 Multitarget 
 
 
Figure 15: A coronal view for MultiTarget 6 MV IMRT plan with isodose lines 
 
For the multitarget case, the IMRT plans consisted of seven beams at angles 
given by TG119 (0o, 100o, 150o, 310o, 260o and 210o). Each field delivered around 30 cGy/ 
fraction to give a total dose of around 210 cGy/ fraction to the isocenter. In the VMAT 
plans, we used a single arc to deliver the dose.  
The ion chamber measurements take place in the center of each target. The 
isocenter is in the middle of the central target and then we apply two shifts to the centers 
of the other two cylinders and measure. The film measurement is taken only in mid-
plane since the shifts are in a superior-inferior (sup – inf) direction. 
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2.1.4 Cshape 
For this site, we created two plans that vary in complexity. One is simple (easy) 
and the other is difficult (hard) with impossible constraints. The purpose of the hard one 
is to test the upper limits of the system. In the easy plan, the core is supposed to get 50% 
of the target dose while the hard plan aims for 20%.  
The beam arrangements for the IMRT plans are 9 beams at 40 degree intervals 
from the AP beam.  For VMAT plans, the Cshape easy had one arc (360 degrees) while 
the hard one consisted of two arcs. The measurements took place at the center of the 
core for the ion chamber and mid-plane for films. We then applied a 2.5 cm shift 
anteriorly to measure at the high dose/low gradient region in the target. 
2.1.5 Prostate 
This test mimics a prostate case with the rectum being the organ at risk of 
interest. The isocenter is the center of the PTV while the mid-rectum is 2.5 cm posterior 
to isocenter. Both ion chamber and film measurements are taken at isocenter and 2.5 cm 
posteriorly. The IMRT plan was composed of seven fields at 0o, 50°, 100o, 150o, 310o, 260o 
and 210o. We used a single arc for the VMAT plans.   
2.1.6 TG119 Head and Neck 
The IMRT plans, in this case, consist of nine beams at 40 degree intervals from 
the AP field while the VMAT plan had two arcs. The ion chamber measurements are 
taken at the isocenter (mid PTV) and 4.0 cm posteriorly at the center of the cord. Film 
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measurements were acquired at mid-phantom, including both PTV and parotids, and at 
4.0 cm posteriorly for cord measurements. 
2.1.7”Real” Head and Neck Case 
The ion chamber measurement results for 10 MV and 10 MVFFF TG119 HN 
failed to meet an action level of less than 3% error. As a result we chose an actual “real” 
patient case that was treated at Duke University Medical Center and performed the tests 
on it. The IMRT beams were at the following angles: 180, 140, 100, 60, 20, 340, 300, 260 
and 220 degrees, and the VMAT plans had two arcs. The isocenter measurements were 
in the PTV (or mid-plane for films) and then a posterior shift was taken for low dose 
region measurements.  
 
Figure 16:”Real” head and neck case from Eclipse 
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2.2 Measurements Analysis 
We compared our measurements to the planned doses using a 0.01 cc ion 
chamber for point measurements, films for 2D and Delta4 for 3D analysis. We also 
calculated the confidence levels, as described below, for each method and compared 
them to each of the TG119 institutions’ confidence levels. This requires comparing each 
of 6 MV IMRT, 6 MV FFF IMRT, 6 MV VMAT, 6 MV FFF VMAT, 10 MV IMRT, 10 MV 
FFF IMRT, 10 MV VMAT and 10 MV FFF VMAT to the TG119’s 6 MV IMRT results. The 
paired student’s t-test was used to determine the statistical significance between IMRT 
and VMAT, 6 MV and 10 MV energies and FF and FFF. The Delta 4 results were 
compared in a pass/fail fashion to the ion chamber results for all plans. Gamma criteria 
were set for 3% dose difference (DD) and 3mm distance to agreement (DTA), global 
gamma. In addition to the above, we analyzed film data for 6 MV and 6 MV FFF and 
compared them to the film results given by the six film contributing institutions of 
TG119. 
For ion chamber measurement analysis, we compared our measured doses to the 
planned doses, [error = (measured – planned) / Rx]. EDR2 films were used for the planar 
analysis of IMRT and VMAT plans for 6 MV and 6 MV FFF energies. The films were 
inserted and exposed at a depth of 7.5 cm in a solid water phantom and then compared 
against a calibration film. Unlike the TG119 method where they normalized to ion 
chamber measurements in a corresponding point or area, we matched between 
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measurement and plan in a high dose-low gradient region to get a relative comparison. 
We used a Vidar (Vidar Systems Corporations, Herndon, VA) scanner to scan the films 
and then used the OmniPro software (IBA Dosimetry, Schwarzenbruck, Germany) to 
analyze them. Films were analyzed using gamma index. The gamma index is a 
quantitative description of how well the measured planar dose matches the planned 
dose. The index is composed of two variables: the dose difference between measured 
and planned values at a given point (DD, chosen here to be 3%) and the distance to 
agreement (DTA, chosen to be 3mm) which is the distance between a measured point 
and the closest point in the plan that exhibits equal dose [24]. The pseudo 3D 
measurements were also analyzed using the gamma index, with criteria of 3%, 3mm 
with 5% threshold. 
In addition, we used the confidence level (CL) as defined and recommended by 
TG119. The CL for a group of measurements is given by CL = | mean | + 1.96 SD. The 
formula accounts for both systematic errors (in the mean deviation) and random errors 
(in the standard deviation). The calculated CL encompasses roughly 97.5% of the data, 
assuming an even distribution about the mean.  TG119 used the data of all institutions as 
its input for determining an overall CL that any individual institution should be able to 
achieve. In our study, we calculated a CL for a variety of measurement groupings (all 
IMRT measurements, all FFF measurements, all 6 MV measurements) to use to compare 
the accuracy and stability of a variety of treatment delivery methods. For ion chamber 
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measurements, the mean deviation was the percentage-error between measurement and 
planned doses. For film and Delta4 measurements, the mean deviation was the 
percentage of pixels failing to meet the gamma criteria. 
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3. Results  
3.1. Planning Results 
Tables A through D in Appendix A show the planning goals for each site along 
with our planning results in comparison to TG119 institutions and whether the goals are 
achieved within two standard deviations of the TG119 institutions. 
All planning results achieved the goals set by TG119 ± 2 standard deviation, with 
the exception of 6 MV FFF VMAT plans. The PTV and Core D10 of Cshape easy and 
Core D10 in Cshape hard, specifically, failed to meet the criteria. In addition, the 10 MV 
FFF ”real” HN VMAT plan did not meet the PTV’s D20 TG119 criteria. However, the 
planning for this case was from a real case that has been treated at Duke University 
Hospital and the constraints were not set based on TG119. 
 
3.2. Bands: Film Measurements 
The points passing gamma criteria for 6 MV and 6 MV FFF are 98.90% and 
98.81% respectively. The analysis for this test, as well as for other film data, was done 
relative to the planned plane by matching a point in high dose/low gradient region in 
the measured plane to a similar point in the plan. We did not measure the central dose 
using an ion chamber while acquiring the films. 
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3.3. Site-specific Cases: Measurements Results 
We collected data for six sites using ion chamber and Delta4 ( MultiTarget, 
Cshape easy, Cshape hard, TG119 HN, ”real” HN case and Prostate) using all 
combinations of 6 MV/10MV, IMRT/VMAT and FF/FFF. Film measurements were done 
for the five cases given by TG119 using IMRT and VMAT for energies 6 MV and 6 MV 
FFF. 
3.3.1. Ion Chamber Results 
a) Measured Dose vs. Planned Dose 
The results of ion chamber measurements are shown in Figures 17 to 24. These 
results represent the error which must be within 3% to pass. The error represents the 
discrepancy between our planned doses and measured doses, with error is defined as 
error = (measured dose – planned dose)/prescribed dose. The figures show the %error 
for each energy and mode in each case. Each figure includes the average of the TG119 
institutions with the error bars being 2 standard deviations as given by the TG119 
report. 
The majority of the ion chamber measurements (94%) agreed with the planned 
doses to within 3%. The majority of errors > 3% involved the HN IMRT plans, either 
TG119 or “real”. All 6 MV & 6 MV FFF measurements had errors <= 3%, except for one 6 
MV FFF with an error of 3.3% (TG119 HN IMRT). All 10 MV measurements were within 
3% of planned doses except for one deviation (-5.7%, TG119 HN IMRT).The majority of 
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the discrepancies were found with 10 MV FFF IMRT plans, three of which involving HN 
IMRT plans (-3.2%, -4.9%, -3.3%) and one involving the Cshape Hard plan (+3.8%). All 
failing measurements were confirmed by re-measuring with ion chamber. 
 
 
 
 
 
Figure 17: IMRT cases for 6 MV with flattening filter, high dose 
regions (first 6 sites to the left) and low dose regions (7 sites to the right) 
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Figure 18: VMAT cases for 6 MV with flattening filter, high dose regions 
(first 6 sites to the left) and low dose regions (7 sites to the right) 
Figure 19: IMRT cases for 6 MV flattening filter free (FFF), high dose 
regions (first 6 sites to the left) and low dose regions (7 sites to the right) 
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Figure 20: VMAT cases for 6 MV flattening filter free (FFF), high 
dose regions (first 6 sites to the left) and low dose regions (7 sites to the 
Figure 21: IMRT cases for 10 MV with flattening filter free, high dose 
regions (first 6 sites to the left) and low dose regions (7 sites to the right) 
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Figure 22: VMAT cases for 10 MV with flattening filter free, high dose 
regions (first 6 sites to the left) and low dose regions (7 sites to the right) 
Figure 23: IMRT cases for 10 MV flattening filter free (FFF), high dose 
regions (first 6 sites to the left) and low dose regions (7 sites to the right) 
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b) Measured Data vs. TG119 
In figures 10 through 17 we present our measurements in comparison with the 
TG119 institutions measurements for each plan. All ion chamber measurements agreed 
with the (mean + 2SD) from TG119 except for the 10 MV IMRT TG119 HN plan (both FF 
and FFF). In addition, we calculated the confidence level, defined previously as CL = 
|mean|+1.96SD, and compared the measured results to the TG119 institutions as shown 
in Figures 25, 26 and 27; and Table 1. 
 
 
 
Figure 24: VMAT cases for 10 MV flattening filter free (FFF), high dose 
regions (first 6 sites to the left) and low dose regions (7 sites to the right) 
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Figure 25: Confidence levels of different TG119 institutions in high dose 
regions and low dose regions 
Figure 26: Confidence levels of different energies and modes in high dose 
regions and low dose regions in our study 
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Table 1: Comparison of Measured Confidence Level for 6 MV vs. 10 MV, FF vs. 
FFF, and IMRT vs. VMAT with and without the 10 MV HN Measurements 
 Confidence Limit 
All IC measurements 3.5% 
All IC excluding 10 MV HN 3.1% 
 6 MV 10 MV 
All ion chamber measurements 3.5% 4.7% 
All IC excluding 10 MV HN 3.5% 3.3% 
 FF FFF 
All ion chamber measurements 3.7% 4.5% 
All IC excluding10 MV HN 2.8% 4.0% 
Figure 27: Confidence levels of different energies and modes in high dose 
regions and low dose regions of our study excluding the head and neck cases for 10 
MV and 10 MV FFF 
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 IMRT VMAT 
All ion chamber measurements 4.2% 2.8% 
All IC excluding 10 MV HN 3.3% 2.9% 
 High Dose Region Low Dose Region 
All ion chamber measurements 4.1% 2.9% 
All IC excluding 10 MV HN 3.4% 2.7%  
 
c) Statistical Analysis 
We used the student’s paired t-test to find the p-values and evaluate the 
statistical significance of VMAT vs. IMRT, FFF vs. FF and high dose region vs. low dose 
region. This paired t-test uses the null hypothesis, assuming that the mean of the 
population of difference scores across the two measurements is zero. This would 
indicate that there is no statistically significant difference between the two groups being 
tested.  We separated our data into many groupings, sorting by energy (6 MV & 10 MV), 
delivery technique (IMRT & VMAT), & machine design (FF & FFF). The groupings share 
from the same data population. For example, the second row of Table 2 compares 
VMAT vs. IMRT for 6 MV plans. This particular analysis compares all 6 MV VMAT 
plans (both FF and FFF) against all 6 MV IMRT plans (both FF and FFF).  The third row 
compares FF vs. FFF for 6 MV plans. This analysis then separates the data into 6 MV FF 
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plans (both VMAT and IMRT) and 6 MV FFF plans (both VMAT and IMRT). This 
pattern is continued throughout Table 2. 
Table 2: Statistical Differences for VMAT vs. IMRT, FFF vs. FF, and High vs. 
Low Dose Region Ion chamber Measurements Based on the Student's Paired T-Test 
Energy N (number of 
data pairs) 
Tests p-value Statistically 
Significant 
6 MV 24  VMAT vs. 
IMRT 
0.221 No 
24  FFF vs. FF 0.022 Yes 
24  High vs. Low 0.059 No 
10 MV 24  VMAT vs. 
IMRT 
0.358 (0.949 w/o HN) No 
24  FFF vs. FF 0.894 (0.500 w/o HN) No 
24  High vs. Low 0.004 (0.015 w/o HN) Yes 
6 MV and 
10 MV 
48  VMAT vs. 
IMRT 
0.046 (0.212 w/o 10 
MV HN) 
Yes (No) 
48  FFF vs. FF 0.099 (0.193 w/o 10 
MV HN) 
No 
48  High vs. Low 0.002 (0.008 w/o 10 
MV HN) 
Yes 
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3.3.2. Film Results 
As in TG119, we did a composite plan delivery and comparison (not field by 
field) with the coronal film plane at isocenter. We applied shifts to the HN, Cshape, and 
prostate plans to measure a second coronal plane per TG119. 
a) Measured Dose vs. Planned Dose 
We analyzed the films using gamma criteria of 3% DD, 3mm DTA and 20% 
threshold (figures 28 and 29). The 20% threshold was selected based on the lowest dose 
point measured by the calibration film. The only exception was the two prostate-shifted 
film measurements, which used a 40% threshold to eliminate contamination from the 
processor. All films met the acceptability criteria of <= 10% of pixels failing gamma. 
 
 
 
 
 
 
 
 
 
 
Figure 28: A high dose region comparison between film data for 6 MV, 6 
MV FFF and TG119 institutions 
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b) Measured Data vs. TG119 
Figure 30 shows a plan by plan comparison of the average error in the 
TG119 institutions. Inspection of these figures will show that our plans are 
comparable to those in TG119. Further, we calculated the confidence limit in a 
similar fashion to those regarding the ion chamber measurements, with the 
definition here being (CL = 100 - |mean|+1.96SD). The mean, in this case, is the 
percentage of points passing the gamma criteria. The compiled results for our 
study and the TG119 institutions are shown in Figure 31. 
Figure 29: A low dose region comparison between film data for 6 MV, 6 
MV FFF and TG119 institutions 
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Figure 30: Mean % pixels failing gamma comparing TG119 institutions and 
measured data 
Figure 31: Confidence limit (% pixels failing gamma) comparing TG119 
institutions and measured data 
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c) Statistical Analysis 
Similar to the ion chamber analysis above, this is also testing the validity of the 
null hypothesis.  The groups involved are 6 MV VMAT plans (FF and FFF) vs. 6 MV 
IMRT plans (FF and FFF), 6 MV FFF plans (VMAT and IMRT) vs. 6 MV FF plans (VMAT 
and IMRT), and 6 MV measurements in high dose regions (VMAT, IMRT, FF, and FFF 
plans) vs. low dose regions (VMAT, IMRT, FF, and FFF plans).We used the student’s 
paired t-test comparing the fraction of points failing the gamma criteria in our plans, 
with the resulting p-values shown in Table 3. 
Table 3: Statistical Differences for VMAT vs. IMRT, FFF vs. FF, and High vs. Low 
Dose Region 6MV Film Measurements Based on the Student's Paired T-Test  
Tests N (number of 
data pairs) 
p-value Statistically Significant 
VMAT vs. IMRT 18  0.104 No 
FFF vs. FF 18  0.922 No 
High vs. Low 16  0.124 No 
 
3.3.3. Delta4 Results 
As an addition to the ion chamber and film measurements, we collected 3D 
dosimetric data for comparison.   
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a) Measured Dose vs. Planned Dose 
Gamma parameters of 3% - 3mm with a 5% threshold were used (Table 4). All 
plans met acceptability criterion of 90% of pixels passing (average 99.7% +/- 
0.8%). A second analysis was performed using 2%, 2mm gamma parameters 
(Table 5), where almost all plans met the 90% passing rate criteria (average 98.9% 
+/- 2.5%). The associated confidence limits are 1.9% failing (98.1% passing) for 3% 
DD, 3mm DTA and 6.0% failing (94% passing) for 2%, 2mm. 
 
Table 4: Gamma 3%, 3 mm Passing Points Percentage for all Plans of all         
Energies 
 
6 MV 6 MV FFF 10 MV 
10 MV 
FFF 
Cshape 1 IMRT 100.0% 100.0% 100.0% 100.0% 
Cshape 1 VMAT 99.9% 100.0% 100.0% 100.0% 
Cshape 2 IMRT 100.0% 100.0% 100.0% 100.0% 
Cshape 2 VMAT 100.0% 100.0% 99.9% 100.0% 
H&N IMRT 99.6% 97.0% 98.2% 99.9% 
H&N VMAT 100.0% 99.9% 100.0% 100.0% 
MultiTarget IMRT 100.0% 100.0% 100.0% 100.0% 
MultiTarget VMAT 99.7% 100.0% 100.0% 100.0% 
Prostate IMRT 100.0% 100.0% 100.0% 100.0% 
Prostate VMAT 100.0% 100.0% 100.0% 100.0% 
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“Real” H&N IMRT 98.3% 98.6% 98.4% 98.5% 
“Real” H&N VMAT 96.7% 99.8% 100.0% 99.0% 
 
 
Table 5: Gamma 2%, 2 mm Passing Points Percentage for all Plans of all 
Energies 
 
6 MV 6 MV FFF 10 MV 
10 MV 
FFF 
Cshape 1 IMRT 100.0% 99.9% 99.4% 99.8% 
Cshape 1 VMAT 99.1% 100.0% 98.1% 99.7% 
Cshape 2 IMRT 100.0% 99.8% 99.8% 99.5% 
Cshape 2 VMAT 100.0% 100.0% 99.0% 99.9% 
H&N IMRT 94.3% 95.2% 87.6% 91.5% 
H&N VMAT 98.5% 99.8% 100.0% 99.7% 
MultiTarget IMRT 100.0% 99.9% 99.9% 100.0% 
MultiTarget VMAT 99.7% 98.2% 99.7% 99.5% 
Prostate IMRT 100.0% 100.0% 100.0% 100.0% 
Prostate VMAT 100.0% 100.0% 100.0% 100.0% 
“Real” H&N IMRT 93.4% 96.5% 95.7% 96.6% 
“Real” H&N VMAT 85.9% 94.5% 99.0% 91.9% 
 
 
 
 48 
b) Measured Data vs. TG119 
3D data was not collected by TG119, so no direct comparison can be made to its 
results. However, we used the confidence limit (CL) methodology of TG119 to calculate 
appropriate limits for our 3D dose measurements. To follow the ion chamber analysis, 
all calculations were done with and without the 10 MV H&N data. 
Table 6: Confidence Limits (% Pixels Failing Gamma) for 3%, 3mm and 2%, 
2mm Gamma Criteria 
  3%, 3mm 2%, 2mm 
  Confidence Limit Confidence Limit 
All Delta4 
Measurements 
1.9% 6.0% 
All Delta4 – 10 MV 
HN 
1.8% 3.1% 
  6 MV 10 MV 6 MV 10 MV 
All Delta4 
Measurements 
2.3% 1.4% 8.5% 8.3% 
All Delta4 – 10 MV 
HN 
2.3% 0.0% 8.5% 1.3% 
  FF FFF FF FFF 
All Delta4 
Measurements 
2.0% 1.7% 9.8% 6.7% 
All Delta4 – 10 MV 
HN 
1.9% 1.7% 8.5% 4.2% 
  IMRT VMAT IMRT VMAT 
All Delta4 
Measurements 
2.1% 1.6% 8.7% 8.0% 
All Delta4 – 10 MV 
HN 
1.9% 1.6% 5.3% 7.8% 
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c) Statistical Analysis 
The validity of the standard null hypothesis was evaluated. The groupings were 
similar to those tested in Table 2. For example, the 6 MV VMAT vs. IMRT compares 6 
MV VMAT plans (FF and FFF) vs. 6 MV IMRT plans (FF and FFF). We used the 
student’s paired t-test comparing the fraction of points failing the gamma criteria in our 
plans, with the resulting p-values shown in Tables 7 and 8 on the following page. No 
statistically significant differences were observed. 
 
Table 7: Statistical Differences for VMAT vs. IMRT and FFF vs. FF 3D 
Measurements Based on the Student's Paired T-Test 
3%, 3 mm Gamma Analysis 
Energy N (Number of 
data pairs) 
Tests p-value Statistically 
Significant 
6 MV 12 VMAT vs. 
IMRT 
0.506 
No 
12 
FF vs. FFF 
0.8 
No 
10 MV 12 VMAT vs. 
IMRT 
0.116 (0.351 w/o HN) 
No 
12 
FF vs. FFF 
0.669 (0.351 w/o HN) 
No 
6 MV & 
10 MV 
24 VMAT vs. 
IMRT 
0.143 (0.514 w/o 10 MV 
HN) No 
24 
FF vs. FFF 
0.668 (0.777 w/o 10 MV 
HN) No 
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Table 8: Statistical Comparison of 2% / 2mm Gamma Analysis of 3D Data 
2%, 2 mm Gamma Analysis 
Energy N (Number of 
data pairs) 
Tests p-value Statistically 
Significant 
6 MV 12 VMAT vs. 
IMRT 
0.76 
No 
12 
FF vs. FFF 
0.182 
No 
10 MV 12 VMAT vs. 
IMRT 
0.318 (0.143 w/o HN) 
No 
12 
FF vs. FFF 
0.991 (0.211 w/o HN) 
No 
6 MV & 
10 MV 
24 VMAT vs. 
IMRT 
0.492 (0.586 w/o 10 MV 
HN) No 
24 
FF vs. FFF 
0.321 (0.112 w/o 10 MV 
HN) No 
 
 
d) Delta4 vs. Film 
We used the Pearson Correlation Coefficient and Spearman’s Rho calculations to 
determine if the film and Delta4 results were correlated (Table 9). The Pearson 
Correlation Coefficient is used to estimate the strength of a linear relationship between 
two variables. Spearman's Rho, on the other hand, estimates the strength of a monotonic 
relationship between two variables. For both tests, r = +/-1 would be a perfect 
positive/negative correlation.  
 All tests showed a weak positive correlation between the data. A plan-by-plan 
comparison is displayed in Figure 32 below. 
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Table 9: Film – Delta4 Data Correlation 
 Pearson Correlation 
Coefficient (r) 
Spearman’s Rho (R) 
Film (3%, 3mm) vs. Delta4 (3%, 3mm) 0.440 0.462 
Film (3%, 3mm) vs. Delta4 (2%, 2mm) 0.200 0.403 
 
 
 
 
Figure 32: Correlation between film results and Delta4 results 
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3.4. Pion Effect 
The ion recombination correction factor (Pion) corrects for the loss of ions in the 
chamber due to the general recombination, initial recombination and diffusion against 
the electric field [11]. Pion can be measured by taking readings at two different bias 
voltages and the ratio of the readings lead to Pion [13].  
Pion = (1 – VH / VL) / (MH / ML – VH /VL)   [14] 
In the above equation, VH is the operating voltage and VL is half of VH; MH and ML are 
the raw ion chamber readings at VH and VL.  
Wang et al. showed that the removal of the Flattening Filter can affect the ion 
recombination in the ion chamber [15]. This effect can be due to the increased dose rate, 
the main advantage of the Flattening Filter Free mode. We studied the difference 
between using the flattened beam versus the softer flattening filter free one on the Pion.  
Given that the recombination effect is a function of dose per pulse (MU/min), we 
tested the effect on a FFF beam by comparing Pion for 6 MV to 6 MV FFF at the isocenter. 
We delivered 200 MUs in each measurement and set the field size to 10x10 cm2 and 100 
cm SSD. Table 10 shows the Pion values for 6 MV and 6 MV FFF with the chamber at 
various depths. 
This test showed an insignificant difference between the Pion for 6 MV FF and 6 
MV FFF beams (less than 0.5%), in agreement with Wang’s results. Wang studied the 
variation in Pion between flat and FFF beams for 6 MV and 10 MV using three different 
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chambers. They used an SAD setup with a chamber depth of 10 cm and field size of 10x 
10 cm2. They reported that all measured Pion  fell between 1% and 1.02 % [15]. 
Table 10: Pion Values for 6 MV and 6 MV FFF with the Chamber Inserted in 
Different Depths 
Depth (cm) 6 MV Pion 6 MV FFF Pion 
1.5 1.006 1.004 
7.5 1.009 1.005 
15.0 1.008 1.007 
 
3.5. High Dose Rate Effect 
The main advantage of having a flattening filter free beam is the availability to 
treat using very high dose rates, which results in a shorter treatment time. We compared 
our ion chamber and Delta4 measurements for 6 MV FFF with dose rates from 400 
MU/min to 1400 MU /min and the results were comparable to each other. These results 
are similar to published findings [16]. 
We chose a 6 MV FFF TG119 HN IMRT case to conduct this test. We tested the 
effect of high dose rate by gradually increasing the dose rate from 600 MU/min to 1400 
MU/min, and then took measurements using the cc01 ion chamber. We also took Delta4 
measurements for the same dose rates and the results were identical through the 
different dose rates. The ion chamber’s percentage difference is shown in Table 11. 
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Table 11: Ion Chamber Measurement vs. Planned Results  
Dose Rate (MU/min) % Difference 
600 0.1% 
1000 -0.3% 
1200 -0.4% 
1400 -0.6% 
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4. Discussions 
4.1. Planning Results 
From the data in Tables A through D in Appendix A, we found that all IMRT 
plans and most of the VMAT plans achieved the TG119 planning goals within two 
standard deviations of the TG119 institutions. The four goals in FFF VMAT plans that 
did not meet the criterion are: 6 MV FFF Cshape (easy), where we noticed that D10 for 
both PTV and the core are too high; D10 of the core in Cshape (hard) is also much higher 
than the goal; and D20 is much higher than the TG119 goal in the ”real” HN case. The 
“real” HN case was not compared to TG119 institutions since they did not have a similar 
case.  
4.2. Bands Results 
The bands results of 98.81% and 98.90% for 6 MV and 6 MV FFF which suggests 
that our film processor/scanner system is acceptable. These results fall within the range 
of the four TG119 institutions that submitted the gamma passing rates for their bands 
film measurements. 
4.3. Test Cases  
4.3.1. Ion Chamber 
The majority (94%) of ion chamber measurements passed an acceptance criterion 
of +/-3% agreement with the planned dose, indicating that all energies and modalities 
tested were adequately commissioned. This result supports our first hypothesis, that 
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TG119 methodology may be used for commissioning VMAT and FFF in addition to the 
traditional IMRT and FF. Measurements that failed both Duke and TG119 acceptance 
criteria were associated with a site/energy combination (10 MV for HN plans) that 
would not be clinically used. For that challenging situation, VMAT provided better 
agreement with planned doses than IMRT, perhaps because of the greater degrees of 
freedom offered by a double-arc beam arrangement.  Switching to a “real” HN case 
instead of the TG119 clinical case provided more forgiving geometry, enabling an 
improved agreement between 10 MV planned and measured doses. Our clinical 
recommendation is to restrict TG119 testing to site/energy/delivery technique 
combinations that will be in clinical use.  
The confidence limits calculated from our measurements are generally in good 
agreement with the +/-3% acceptance criterion when the 10 MV HN data is removed.  
The measured results are biased by pre-knowledge of that criterion, such that any 
measurements with errors >3% were re-measured while measurements within 3% 
typically were not. The 6 MV and 10 MV confidence limits were similar (3.5% & 3.3%), 
indicating a similar measurement uncertainty. The IMRT and VMAT confidence limits 
(3.3% & 2.9%) were likewise similar. More uncertainty was seen with FFF (4.0%) than FF 
(2.8%). Measurements in the low dose region (2.7%) had less uncertainty than in the 
high dose region (3.4%), because the error was calculated relative to the prescription 
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dose rather than the local dose. The larger absolute dose differences possible in the high 
dose region increase its uncertainty. 
In general, the difference in ion chamber measurements for IMRT vs. VMAT, FFF 
vs. FF, and high dose region vs. low dose region were statistically insignificant. FFF vs. 
FF was statistically significant, but only for 6 MV (average error: -0.9% vs. -0.2%). The 
difference is larger when only 6 MV IMRT plans are evaluated (p = 0.0018, average error: 
1.3% FFF vs. -0.2% FF). There were no statistically significant differences between FF and 
FFF with either the 10 MV data or the combined energy data. This indicates that the 
difference may originate in the modeling of the 6 MV FFF beam or in some interaction of 
a FFF delivery with a low energy beam causing higher uncertainty. While VMAT vs. 
IMRT with combined energies is statistically significant, the significance disappears with 
the 10 MV HN case is removed. The lack of statistically significant differences between 
VMAT/IMRT and FF/FFF measurements supports the hypothesis that TG119 
methodology is appropriate for commissioning VMAT & FFF. The difference between 
high and low dose measurements was statistically significant as expected, for the same 
reason discussed above: calculating the error relative to the prescription dose rather than 
the local dose. 
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4.3.2. Film  
All film planes met the acceptability criterion of <= 10% of pixels failing 3%, 3mm 
gamma.  Our passing rates were typically equal to or better than those reported in 
TG119. The overall TG119 film confidence limit was 12.4% of pixels failing, compared to 
our measured confidence limit of 6% of pixels failing. These results indicate a successful 
commissioning of VMAT/IMRT and FF/FFF modes for the 6 MV energy at Duke. No 
statistically significant differences were found between VMAT/IMRT, FF/FFF, and 
high/low dose regions. The film results support the hypothesis that TG119 methodology 
may be used for commissioning VMAT and FFF. 
4.3.3. Delta4 
Part of the challenge of analyzing 3D dose measurements is the determination of 
appropriate gamma criteria.  In this analysis we have examined both 3%, 3mm and 2%, 
2mm criteria.  The passing rates with 3%, 3mm were very high for all films. While this 
indicates that all energies/modalities were adequately commissioned, it does not allow 
us to separate out the hard-to-achieve plans from the easy-to-achieve plans. Using 2%, 
2mm criterion provides us with more information for analysis. The detrimental impact 
of including 10 MV HN plans is clear (6% confidence level with 10 MV HN plans vs. 3% 
without). The 6 MV and 10 MV confidence limits appear very different when the 10 MV 
HN plans are removed (8.5% vs. 1.3%), but we believe that is due to removing the 
hardest-to-achieve plans (HN) from the 10 MV energy analysis while leaving them in the 
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6 MV energy analysis. With all HN plans included, there is no difference in the 
confidence limit between 6 MV and 10 MV.  While not statistically significant, the 
passing rates were higher for FFF than FF plans, indicating that the new FFF technology 
was adequately commissioned.  There was no statistically significant difference between 
IMRT and VMAT plans. These results support the hypothesis that TG119 methodology 
is appropriate for commissioning VMAT and FFF. 
We included the Delta4 3D dose measurements in this study because many 
clinics no longer have the ability to measure 2D film data.  Could Delta4 be used to 
replace film measurements for commissioning?  Unfortunately, no clear correlation was 
found between film and Delta4 data. While some plans had lower passing rates for both 
film and Delta4 (e.g. 6 MV FFF IMRT HN) others had a dramatically lower passing rate 
for one modality but not the other (e.g. 6 MV IMRT Prostate). Our data do not support 
replacing film with Delta4 (3D) measurements, disproving our second hypothesis. 
Ideally a clinic would use both technologies for the most complete evaluation.   
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5. Conclusions 
The results show that TG119 can be used to test in commissioning IMRT and 
VMAT delivery techniques and of Flattening-Filter and Flattening-Filter-Free modes. 
The commissioning of 6 MV/10 MV, IMRT/VMAT, FF/FFF beam combinations was 
verified using ion chamber (point measurement), film (2D) and multi-planar diode 
(Delta4, 3D) measurements. 
Confidence limits were established for ion chamber (3.1%), film (6%), and Delta4 
(3.1%) measurements. All the confidence limits were comparable to TG119 institutions. 
We recommend that non-clinical plans (e.g. 10 MV HN plans) not be included in TG119 
evaluations. We also recommend that film continue to be used as the gold standard of 
multi-dimensional measurements, rather than be replaced by diode-based technology. 
 
 
 61 
Appendix A 
Table A: 6 MV with FF TrueBeam Planning Results 
Plan Goal(s) TG119- 
Planning 
IMRT (Gy) 
TG119- 
Planning 
VMAT (Gy) 
TG119  
mean + SD 
Achieved 
within 2SD 
MultiTarget Central target  
D99 > 50Gy 
49.98 49.99 49.55 ± 1.62 Yes 
Central target  
D10 < 53Gy 
52.93 54.03 54.55 ± 1.73 Yes 
Superior target 
 D99 > 25Gy 
25.07 24.62 25.16±0.85 Yes 
Superior target  
D10 < 35Gy 
32.05 33.31 34.12±3.04 Yes 
Inferior target  
D99 > 12.5Gy 
13.26 14.07 14.07±1.85 Yes 
Inferior target  
D10 < 25Gy 
23.78 24.24 24.18±2.72 Yes 
Prostate Prostate  
D95 > 75.6Gy 
75.60 75.59 75.66±0.21 Yes 
Prostate D5 < 
83Gy 
79.34 79.75 81.43±1.56 Yes 
Rectum D30 < 
70Gy 
64.29 66.88 65.36±2.97 Yes 
Rectum D10 < 
75Gy 
72.34 74.50 73.03±1.5 Yes 
Bladder D30 < 
70Gy 
40.08 43.68 43.94±8.78 Yes 
Bladder D10 < 
75Gy 
59.82 61.82 62.69±8.15 Yes 
H&N-
TG119 
PTV D90 = 50Gy 50.00 49.18 50.28±0.58 Yes 
PTV D99 > 
46.5Gy 
47.97 47.50 47.04±0.52 Yes 
PTV D20 < 55Gy 52.19 53.26 52.99±0.93 Yes 
Cord max < 
40Gy 
39.19 38.89 37.41±2.50 Yes 
Parotid D50 < 
20Gy 
18.36 18.07 17.98±1.84 Yes 
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Cshape 
(easy) 
PTV D95 = 50Gy 49.98 50.00 50.1±0.17 Yes 
PTV D10 < 55Gy 53.6 54.57 54.4±0.52 Yes 
Core D10 < 
25Gy 
22.32 24.16 22±3.14 Yes 
Cshape 
(hard) 
PTV D95 = 50Gy 49.99 49.99 50.11±0.165 Yes 
PTV D10 < 55Gy 56.22 58.02 57.02±2.2 Yes 
Core D10 < 
10Gy 
14.59 16.30 16.3±3.07 Yes 
H&N-
”real” 
PTV D90 = 50Gy 52.09 51.28 n/a n/a 
PTV D99 > 
46.5Gy 
49.54 49.42 n/a n/a 
PTV D20 < 55Gy 54.64 53.38 n/a n/a 
Cord max < 
40Gy 
23.73 23.63 n/a n/a 
Lt Parotid  
D50 < 20Gy 
15.62 18.49 n/a n/a 
Rt Parotid 
 D50 < 20Gy 
15.32 17.56 n/a n/a 
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Table B: 6 MV FFF TrueBeam Planning Results 
Plan Goal(s) Planning 
IMRT (Gy) 
Planning 
VMAT (Gy) 
TG119 
mean + SD 
Achieved 
within 2SD 
MultiTarget Central target 
D99 > 50Gy 
49.98 49.99 49.55 ± 1.62 Yes 
 Central target 
D10 < 53Gy 
53.27 54.58 54.55 ± 1.73 Yes 
 Superior target 
D99 > 25Gy 
24.64 24.71 25.16±0.85 Yes 
 Superior target 
D10 < 35Gy 
31.55 33.72 34.12±3.04 Yes 
 Inferior target 
D99 > 12.5Gy 
12.53 14.14 14.07±1.85 Yes 
 Inferior target 
D10 < 25Gy 
22.52 24.52 24.18±2.72 Yes 
Prostate Prostate D95 > 
75.6Gy 
75.59 75.59 75.66±0.21 Yes 
 Prostate D5 < 
83Gy 
79.56 80.02 81.43±1.56 Yes 
 Rectum D30 < 
70Gy 
64.20 66.88 65.36±2.97 Yes 
 Rectum D10 < 
75Gy 
72.43 74.53 73.03±1.5 Yes 
 Bladder D30 < 
70Gy 
39.83 43.86 43.94±8.78 Yes 
 Bladder D10 < 
75Gy 
58.77 61.84 62.69±8.15 Yes 
H&N PTV D90 = 
50Gy 
50.00 49.95 50.28±0.58 Yes 
 PTV D99 > 
46.5Gy 
47.89 47.51 47.04±0.52 Yes 
 PTV D20 < 
55Gy 
52.06 53.43 52.99±0.93 Yes 
 Cord max < 
40Gy 
39.26 39.24 37.41±2.50 Yes 
 Parotid D50 < 
20Gy 
17.69 16.93 17.98±1.84 Yes 
Cshape PTV D95 = 49.99 50.02 50.1±0.17 Yes 
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(easy) 50Gy 
 PTV  
D10 < 55Gy 
53.82 65.71 54.4±0.52 Yes IMRT / 
 NO VMAT 
 Core D10 < 
25Gy 
21.49 63.35 22±3.14 Yes IMRT /  
NO VMAT 
Cshape 
(hard) 
PTV  
D95 = 50Gy 
49.98 49.99 50.11±0.165 Yes 
 PTV  
D10 < 55Gy 
56.44 60.50 57.02±2.2 Yes 
 Core  
D10 < 10Gy 
14.24 32.81 16.3±3.07 Yes IMRT / 
NO VMAT 
H&N-
”real” 
PTV D90 = 
50Gy 
52.09 49.99 n/a n/a 
 PTV D99 > 
46.5Gy 
49.43 46.28 n/a n/a 
 PTV D20 < 
55Gy 
54.97 58.78 n/a n/a 
 Cord max < 
40Gy 
23.42 23.28 n/a n/a 
 Lt Parotid D50 
< 20Gy 
15.43 15.21 n/a n/a 
 Rt Parotid D50 
< 20Gy 
15.09 17.93 n/a n/a 
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Table C: 10 MV with FF TrueBeam Planning Results 
Plan Goal(s) Planning 
IMRT (Gy) 
Planning 
VMAT (Gy) 
TG119  
mean + SD 
Achieved 
within 2SD 
MultiTarget Central target 
D99 > 50Gy 
49.77 49.98 49.55 ± 1.62 Yes 
 Central target 
D10 < 53Gy 
54.00 54.90 54.55 ± 1.73 Yes 
 Superior 
target D99 > 
25Gy 
24.88 24.46 25.16±0.85 Yes 
 Superior 
target D10 < 
35Gy 
32.21 33.81 34.12±3.04 Yes 
 Inferior target 
D99 > 12.5Gy 
13.08 13.91 14.07±1.85 Yes 
 Inferior target 
D10 < 25Gy 
23.44 25.02 24.18±2.72 Yes 
Prostate Prostate  
D95 > 75.6Gy 
75.59 75.59 75.66±0.21 Yes 
 Prostate  
D5 < 83Gy 
79.81 79.52 81.43±1.56 Yes 
 Rectum 
 D30 < 70Gy 
64.75 67.01 65.36±2.97 Yes 
 Rectum  
D10 < 75Gy 
72.8 74.82 73.03±1.5 Yes 
 Bladder 
D30 < 70Gy 
39.72 42.19 43.94±8.78 Yes 
 Bladder  
D10 < 75Gy 
59.68 60.98 62.69±8.15 Yes 
H&N PTV D90 = 
50Gy 
50.00 49.91 50.28±0.58 Yes 
 PTV D99 > 
46.5Gy 
48.32 47.36 47.04±0.52 Yes 
 PTV D20 < 
55Gy 
51.86 53.10 52.99±0.93 Yes 
 Cord max < 
40Gy 
39.42 38.84 37.41±2.50 Yes 
 Parotid  
D50 < 20Gy 
20.12 18.68 17.98±1.84 Yes 
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Cshape 
(easy) 
PTV D95 = 
50Gy 
49.98 50.00 50.1±0.17 Yes 
 PTV D10 < 
55Gy 
52.68 54.92 54.4±0.52 Yes 
 Core D10 < 
25Gy 
24.76 24.99 22±3.14 Yes 
Cshape 
(hard) 
PTV D95 = 
50Gy 
49.99 50.00 50.11±0.165 Yes 
 PTV D10 < 
55Gy 
53.39 58.25 57.02±2.2 Yes 
 Core D10 < 
10Gy 
21.46 17.13 16.3±3.07 Yes 
H&N-
”real” 
PTV D90 = 
50Gy 
52.02 53.04 n/a n/a 
 PTV D99 > 
46.5Gy 
49.72 48.93 n/a n/a 
 PTV D20 < 
55Gy 
54.48 56.34 n/a n/a 
 Cord max < 
40Gy 
24.55 24.88 n/a n/a 
 Lt Parotid 
 D50 < 20Gy 
17.25 18.95 n/a n/a 
 Rt Parotid  
D50 < 20Gy 
16.55 17.26 n/a n/a 
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Table D: 10 MV FFF TrueBeam Planning Results 
Plan Goal(s) Planning 
IMRT (Gy) 
Planning 
VMAT (Gy) 
TG119 
mean + SD 
Achieved 
within 2SD 
MultiTarget Central target  
D99 > 50Gy 
49.99 49.98 49.55 ± 1.62 Yes 
 Central target 
D10 < 53Gy 
53.86 54.90 54.55 ± 1.73 Yes 
 Superior target 
D99 > 25Gy 
24.70 24.73 25.16±0.85 Yes 
 Superior target 
D10 < 35Gy 
32.73 33.96 34.12±3.04 Yes 
 Inferior target 
D99 > 12.5Gy 
13.01 13.95 14.07±1.85 Yes 
 Inferior target 
D10 < 25Gy 
23.78 23.17 24.18±2.72 Yes 
Prostate Prostate 
 D95 > 75.6Gy 
75.58 75.58 75.66±0.21 Yes 
 Prostate  
D5 < 83Gy 
80.10 79.69 81.43±1.56 Yes 
 Rectum  
D30 < 70Gy 
64.78 67.30 65.36±2.97 Yes 
 Rectum  
D10 < 75Gy 
72.85 74.70 73.03±1.5 Yes 
 Bladder  
D30 < 70Gy 
40.37 43.32 43.94±8.78 Yes 
 Bladder  
D10 < 75Gy 
61.08 62.98 62.69±8.15 Yes 
H&N PTV D90 = 
50Gy 
50.00 49.93 50.28±0.58 Yes 
 PTVD99 > 
46.5Gy 
48.16 47.34 47.04±0.52 Yes 
 PTV D20 < 
55Gy 
51.89 53.34 52.99±0.93 Yes 
 Cord max < 
40Gy 
39.22 39.04 37.41±2.50 Yes 
 Parotid D50 < 
20Gy 
18.83 17.77 17.98±1.84 Yes 
Cshape 
(easy) 
PTV  
D95 = 50Gy 
50.00 49.97 50.1±0.17 Yes 
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 PTV  
D10 < 55Gy 
53.44 55.52 54.4±0.52 Yes 
 Core 
 D10 < 25Gy 
25.29 24.50 22±3.14 Yes 
Cshape 
(hard) 
PTV  
D95 = 50Gy 
50.00 49.93 50.11±0.165 Yes 
 PTV  
D10 < 55Gy 
53.73 58.35 57.02±2.2 Yes 
 Core 
 D10 < 10Gy 
18.53 15.56 16.3±3.07 Yes 
H&N-
”real” 
PTV D90 = 
50Gy 
52.05 49.98 n/a n/a 
 PTV D99 > 
46.5Gy 
49.57 45.55 n/a n/a 
 PTV D20 < 
55Gy 
54.71 64.06 n/a n/a 
 Cord max < 
40Gy 
23.88 23.17 n/a n/a 
 Lt Parotid  
D50 < 20Gy 
16.24 17.64 n/a n/a 
 Rt Parotid  
D50 < 20Gy 
15.46 15.76 n/a n/a 
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